Literature DB >> 22081292

Inpatient warfarin management: pharmacist management using a detailed dosing protocol.

Nancy L Dawson1, Ivan E Porter, Dusko Klipa, William R Bamlet, Mary Ann Hedges, Michael J Maniaci, Jason Persoff, Archana Roy, Alden V Patel.   

Abstract

Hospitalized patients receiving anticoagulants such as warfarin are at increased risk for adverse events because of difficulties maintaining a therapeutic international normalized ratio (INR). We sought to determine whether a detailed warfarin dosing protocol administered by pharmacists with minimal physician oversight significantly reduced the proportion of hospitalized patients with a supratherapeutic INR. We conducted a prospective, nonrandomized trial with patients on cardiology, internal medicine, and family medicine inpatient services who received at least 1 dose of warfarin while hospitalized. The baseline group included 293 patients, and the intervention group comprised 217 patients. Baseline characteristics were similar in each group, except that more patients received antibiotics in the intervention group. The defect rate (INR > 5 after receiving warfarin) in the baseline group was significantly higher than in the intervention group (7.85 vs. 1.85%). Conversely, the percentage of patients with an INR less than 1.7 after 4 warfarin doses was lower in the intervention patients, indicating overall improvement in therapeutic levels. Dosing discussions were required between the pharmacist and a physician for only 6% of intervention patients. The protocol effectively reduced overanticoagulation without increasing under anticoagulation during hospitalization and reduced the need for close physician oversight.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22081292     DOI: 10.1007/s11239-011-0655-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  15 in total

1.  Development and implementation of a pharmacist-managed inpatient warfarin protocol.

Authors:  David L Damaske; Robert W Baird
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

Review 2.  Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly.

Authors:  Laurie G Jacobs
Journal:  Clin Geriatr Med       Date:  2006-02       Impact factor: 3.076

Review 3.  Patient understanding of warfarin therapy: a review of education strategies.

Authors:  Fiona Newall; Paul Monagle; Linda Johnston
Journal:  Hematology       Date:  2005-12       Impact factor: 2.269

4.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Gordon Guyatt; Gregory W Albers; Robert Harrington; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

5.  A randomized trial comparing 5-mg and 10-mg warfarin loading doses.

Authors:  M A Crowther; J B Ginsberg; C Kearon; L Harrison; J Johnson; M P Massicotte; J Hirsh
Journal:  Arch Intern Med       Date:  1999-01-11

6.  Oral anticoagulation in the hospital: analysis of patients at risk.

Authors:  Nancy L Dawson; Dusko Klipa; Angela K O'Brien; Julia E Crook; Melanie W Cucchi; Alden K Valentino
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

7.  Improving anticoagulation control in hospitalized elderly patients on warfarin.

Authors:  Isabelle Gouin-Thibault; Camille Levy; Eric Pautas; Jean-Pierre Cambus; Ludovic Drouet; Isabelle Mahé; Claire Bal Dit Sollier; Marie-Hélène Horellou; Jean-Louis Golmard; Virginie Siguret
Journal:  J Am Geriatr Soc       Date:  2010-01-26       Impact factor: 5.562

Review 8.  Initiating warfarin therapy: 5 mg versus 10 mg.

Authors:  Courtney D Eckhoff; Robert J Didomenico; Nancy L Shapiro
Journal:  Ann Pharmacother       Date:  2004-11-02       Impact factor: 3.154

9.  Survey of pharmacist-managed inpatient anticoagulation services.

Authors:  Katherine W Phillips; Ann K Wittkowsky
Journal:  Am J Health Syst Pharm       Date:  2007-11-01       Impact factor: 2.637

10.  Impact of an inpatient anticoagulation management service on clinical outcomes.

Authors:  Paula J Biscup-Horn; Michael B Streiff; Timothy R Ulbrich; Todd W Nesbit; Kenneth M Shermock
Journal:  Ann Pharmacother       Date:  2008-05-06       Impact factor: 3.154

View more
  7 in total

1.  Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy.

Authors:  Jessica L Cohen; Elena Thompson; Liron Sinvani; Andrzej Kozikowski; Guang Qiu; Renee Pekmezaris; Alex C Spyropoulos; Jason J Wang
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

2.  The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing.

Authors:  Scott E Kasner; Le Wang; Benjamin French; Steven R Messe; Richard Horenstein; Emile R Mohler; James A S Muldowney; Jonas Ellenberg; Stephen E Kimmel
Journal:  Am J Cardiovasc Drugs       Date:  2015-08       Impact factor: 3.571

3.  The impact of pharmacy monitoring and intervention in patients receiving intravenous heparin.

Authors:  Michaela C Lysogorski; Amany K Hassan; Stacie J Lampkin; Richard Geisler
Journal:  Int J Clin Pharm       Date:  2017-05-15

4.  Advantages of a Warfarin Protocol for Long-term Care Pharmacists: a Retrospective Cohort Study.

Authors:  Randall Sargent; Cynthia Brocklebank; Helen Tam-Tham; Tyler Williamson; Patrick Quail; Diana Turner; Neil Drummond
Journal:  Can Geriatr J       Date:  2016-06-29

Review 5.  Optimizing pharmacotherapy in elderly patients: the role of pharmacists.

Authors:  Jeannie K Lee; Samah Alshehri; Hussam I Kutbi; Jennifer R Martin
Journal:  Integr Pharm Res Pract       Date:  2015-08-11

Review 6.  Clinical impact of a pharmacist-led inpatient anticoagulation service: a review of the literature.

Authors:  Tiffany Lee; Erin Davis; Jason Kielly
Journal:  Integr Pharm Res Pract       Date:  2016-05-26

7.  Improving inpatient warfarin therapy safety using a pharmacist-managed protocol.

Authors:  Paul R Daniels; Dennis M Manning; James P Moriarty; Juliane Bingener-Casey; Narith N Ou; John G O'Meara; Daniel L Roellinger; James M Naessens
Journal:  BMJ Open Qual       Date:  2018-04-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.